E Vaccine Monday

Another Monday, another COVID-19 vaccine coming. This is now a tradition. Today's vaccine is the 3rd in a row and the first in which we have stockholding. Moreover, another share I own is in a deal to boost its own capacity in dealing with the virus.

Meanwhile despite lame-duck maneuvers by the Trump gang over certifying Michigan, president-elect Joe Biden has started naming his cabinet and advisers, starting with the key to the kingdom, foreign policy. Antony Blinken is reportedly the new secretary of state and Conde Thomas Greenfield the new UN Ambassador. Janet Yellen will be Treasury Secy. Jake Sullivan will head the National Security Council. My eldest grandchild, who is en route home for a 3-month break in classes, changed his voting site to Atlanta where he is studying from Ohio where he voted earlier. We need every democrat we can get in GA where two of my dual national Israeli cousins once removed also vote. Hanging out with Trump and cashing in on non-public stock information is not going to help Georgia Republicans win the 2 seats in play and control of the whole US Senate.

China is enforcing new discipline not only on the private sector giants but also on its state-owned companies. It is not guaranteeing to pay a steel company which cannot service its bonds and is in default. Alibaba's new CEO Daniel Zhang today came out in favor of Beijing using “timely and necessary anti-trust rules” now that its ANT sub-IPO has crashed out and its former CEO got ousted.

Never assume that recommendations in Barron's boost your shares as I did yesterday. It was wrong.


*Israeli BiolineRX reported on its Q3 and fell sharply because its acute myeloid leukemia drug failed trials which were discontinued. The share crashed nearly 15% at the US opening. Investors focused on the flop rather than other BLRX cancer news. This included positive stem cell mobilization in multiple myeloma with its Motikafortide phase II trial at Columbia U here which requires fewer patients for phase III than expected and the likely full results from the Combat trial of the drug with Keytruda due before the year-end. Its accounts as with any drug startup are loss-making, at minus $4.6 mn this Q3 vs minus $3.9 mn last year. It has $20.8 mn in cash and equivalents so it still has funding to go.

1 2 3 4
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.